List view / Grid view
10 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
24 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
5 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Ponatinib is effective against SCCOHT, a type of ovarian cancer that mostly strikes young women and girls as young as 14 months...
15 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
27 April 2016 | By Victoria White, Digital Content Producer
The guidance recommends paclitaxel and PLDH for treating ovarian cancer that has returned after previous chemotherapy treatment...
22 April 2016 | By Victoria White, Digital Content Producer
TapImmune plans to initiate a Phase II trial of TPIV 200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer...
5 February 2016 | By Victoria White
The companies are to are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) in FRα-positive ovarian cancer...
3 February 2016 | By Victoria White
The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer...
19 January 2016 | By Snehal Chougule, Allied Market Research
Snehal Chougule discusses the ovarian cancer treatment market and recent approvals by the US Food and Drug Administration...
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
Send this to a friend
Follow: